

# PHARMACY POLICY STATEMENT

## Marketplace

For reauthorization :

1. Chart notes must document reduced neurologic disability or reduced frequency of relapses; AND
2. Member's LVEF is being monitored prior to each dose; AND
3. Member has not exceeded the maximum cumulative lifetime dose of 140 mg/m<sup>2</sup>.

If all the above requirements are met , the medication will be approved for an additional 12 months.

### Cancer diagnosis

Any request for oncology use must be submitted through [NantHealth/Eviti](#) portal.

CareSource considers mitoxantrone